TPI-287, a new taxane family member, reduces the brain metastatic colonization of breast cancer cells

Molecular Cancer Therapeutics

Volumn 11, Issue 9, 2012, Pages 1959-1967

  Fitzgerald, Daniel P ^a,e   Emerson, David L ^b   Qian, Yongzhen ^c   Anwar, Talha ^a,f   Liewehr, David J ^a   Steinberg, Seth M ^a   Silberman, Sandra ^d   Palmieri, Diane ^a   Steeg, Patricia S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b BolderPATH   (United States)

^c SAIC FREDERICK INC   (United States)

^d IQVIA   (United States)

^e Otsuka Pharmaceuticals   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; IXABEPILONE; PACLITAXEL; TAXANE DERIVATIVE; TPI 287; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; KINETICS; MICE; MICE, NUDE; MICROTUBULES; PROTEIN MULTIMERIZATION; RATS; TAXOIDS; TISSUE DISTRIBUTION; TUBULIN MODULATORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866085898     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0061     Document Type: Article

References (39)

1. Eisenhauer EA, Vermorken JB. The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs 1998;55:5-30. (Pubitemid 28035122)
2. Rodriguez-Antona C. Pharmacogenomics of paclitaxel. Pharmacogenomics 2010;11:621-3.
3. Trivedi M, Budihardjo I, Loureiro K, Reid TR, Ma JD. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer. Future Oncol 2008;4:483-500.
4. Smoter M, Bodnar L, Duchnowska R, Stec R, Grala B, Szczylik C. The role of Tau protein in resistance to paclitaxel. Cancer Chemother Pharmacol 2011;68:553-7.
5. Li Y, Tang K, Zhang H, Zhang Y, Zhou W, Chen X. Function of Aurora kinase A in Taxol-resistant breast cancer and its correlation with P-gp. Mol Med Report 2011;4:739-46.
6. Lee E, Nichols P, Groshen S, Spicer D, Lee A. GRP78 as potential prodictor for breast cancer response to adjuvant taxane therapy. Int J Cancer 2011;128:726-31.
7. Spicakova T, O'Brien M, Duran G, Sweet-Cordero A, Sikic B. Expression and silencing of microtubule-associated protein Tau in breast cancer cells. Mol Cancer Ther 2010;9:2970-81.
8. Starlard-Davenport A, Lyn-Cook B, Beland F, Pogribny I. The role of UDP-glucuronosyltransferases and drug transporters in breast cancer drug resistance. Exp Oncol 2010;32:172-80.
9. Swanton C, Nicke B, Schuett M, Eckland AC, Ng C, Li QY., et al. Chromosomal instability determines taxane response. Proc Natl Acad Sci U S A 2009;106:8671-6.
10. Galletti E, Magnani M, Renzulli ML, Botta M. Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes. Chem Med Chem 2007;2:920-42.
11. Fellner S, Bauer B, Miller DS, Schaffnik M, Fankhel M, Spruss T, et al. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 2002;110:1309-18. (Pubitemid 35285757)
12. Steeg P, Camphausen K, Smith Q. Brain metastases as preventive and therapeutic targets. Nat Rev Cancer 2011;11:352-63.
13. Lin N, Bellon J, Winer E. CNS metastases in breast cancer. J Clin Oncol 2004;22:3608-17. (Pubitemid 41103668)
14. Patel R, Mehta M. Targeted therapy for brain metastases: improving the therapeutic ratio. Clin Cancer Res 2007;13:1675-1683. (Pubitemid 46952932)
15. Mayer M. A patient perspective on brain metastases in breast cancer. Clin Cancer Res 2007;13:1623-4. (Pubitemid 46952924)
16. Fidler I, Balasubramanian K, Lin Q, Kim S, Kim S-J. The brain microenvironment and cancer metastasis. Mol Cells 2010;30:93-8.
17. Lockman P, Mittapalli R, Taskar K, Rudraruju V, Gril B, Bohn KA, et al. Heterogeneous blood-brain barrier permeability determines drug efficacy in mouse brain metastases of breast cancer. Clin Cancer Res 2010;16:5664-78.
18. Lin Q, Balasubramanian K, Fan D, Kim SJ, Guo L, Wang H, et al. Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels. Neoplasia 2010;12:748-54.
19. Gril B, Palmieri D, Bronder JL, Herring JM, Vega-Valle E, Feigenbaum L, et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 2008;100:1092-103.
20. Gril B, Palmieri D, Qian Y, Ileva L, Bernardo M, Choyke P, et al. Pazopanib reveals a role for tumor cell B-Raf in the prevention of breast cancer brain metastasis. Clin Cancer Res 2010;17:142-53.
21. Qian Y, Hua E, Bisht K, Woditschka S, Skordos K, Liewehr DJ, et al. Inhibition of polo-like kinase-1 prevents growth of metastatic breast cancer cells in the brain. Clin Exp Metastasis 2011;28:899-908.
22. Palmieri D, Bronder JL, Herring JM, Yoneda T, Weil RJ, Stark AM, et al. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res 2007;67:4190-8. (Pubitemid 46815065)
23. Heusele C, Bonne D, Carlier M. Is microtubule assembly a biphasic process-a flurometric study using 4′,6-diamidino-2-pheynylindole as a probe. Eur J Biochem 1987;165:613-20. (Pubitemid 17090843)
24. Bonne D, Heusele C, Simon C, Pantaloni D. 4′, 6-diamidino-2- phenylindole, a fluorescent-probe for tubulin and microtubules. J Biol Chem 1985;260:2819-25.
25. Palmieri D, Lockman P, Thomas F, Hua E, Herring J, Hargrave E, et al. Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer. Clin Cancer Res 2009;15:6148-57.
26. Ferguson T, Wilcken N, Vagg R, Ghersi D, Novak A. Taxanes for the adjuvant treatment of early breast cancer (Review). Cochrane Database Syst Rev 2007;CD004421.
27. Piccart-Gebhart M, Burzykowski T, Buyse M, Sledge G, Carmichael J, Luck H-J, et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patientswith metastatic breast cancer. J Clin Oncol 2008;26:1980-6.
28. Higa G. The microtubule as a breast cancer target. Breast Cancer 2011;18:103-19.
29. Bystricky B, Chau I. Patupilone in cancer treatment. Expert Opin Investig Drugs 2011;20:107-17.
30. Denduluri N, Swain S. Ixabepilone: clinical role in metastatic breast cancer. Clin Breast Cancer 2011;11:130-45.
31. Palmieri C, Krell J, James C, Harper-Wynne C, Misra V, Cleator S, et al. Rechallenging with anthracyclines and taxanes in metastatic breast cancer. Nat Rev Clin Oncol 2010;7:561-74.
32. Vredenburg M, Ojima I, Veith J, Pera P, Kee K, Cabral F, et al. Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance. J Natl Cancer Inst 2001;93:1234-45. (Pubitemid 32816198)
33. Hoffmann J, Fichtner I, Lemm M, Lienau P, Hess-Stumpp H, Rotgeri A, et al. Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases. Neuro Oncol 2008;11:158-66.
34. Freedman RA, Bullitt E, Sun L, Gelman R, Harris G, Ligibel JA, et al. A phase II study of sagopilone (ZK. 219477; ZK-EPO) in patients with breast cancer and brain metastases. Clin Breast Cancer 2011;11:376-383.
35. O'Reilly T, Wartmann M, Brueggen J, Allegrini PR, Floersheimer A, Maira M, et al. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo. Cancer Chemother Pharmacol 2008;62:1045-54.
36. Peereboom DM, Conlin AK, Seidman AD, Brewer C. Phase II trial of patupilone in patients with breast cancer brain metastases. [abstract] In: Neuro-oncology 2008;10:1077.
37. Fough S, Machtay M, Werner-Wasik M, Curran WJ Jr, Bonanni R, Axelrod R, et al. Phase I trial using patupilone (epothilone B) and concurrent radiotherapy for central nervous system malignancies. Int J Rad Oncol Biol Phys 2010;77:1009-16.
38. Lee F, Borzilleri R, Fairchild C, Kim SH, Long BH, Reventos-Suarez C, et al. BMS-247550: a novel epothilone with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001;7:1429-37. (Pubitemid 32708699)
39. Peterson J, Tucker C, Favours E, Chesire PJ, Creech J, Bilups CA, et al. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models. Clin Cancer Res 2005;11:6950-8. (Pubitemid 41428753)